Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte 56 and Dextrose 5% is a crystalloid solution that provides electrolytes and carbohydrates. Dextrose is metabolized to glucose, which is utilized for cellular energy production. The electrolytes (sodium, chloride, potassium, magnesium, and acetate) maintain or restore intravascular volume, acid-base balance, and osmotic gradients. Acetate is metabolized to bicarbonate, providing an alkalinizing effect.
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
Intravenous infusion for fluid and electrolyte replacement in patients with mild to moderate fluid loss,Source of calories (dextrose) and electrolytes,Maintenance of hydration and electrolyte balance,Treatment of metabolic acidosis (alkalinizing effect from acetate),Off-label: Use as a vehicle for drug administration
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
Intravenous infusion; dose depends on fluid and electrolyte requirements. Typical adult dose: 500-1000 m L as a single infusion, rate up to 333 m L/hour. Maximum 3 L/24 hours.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
Not applicable; composition-dependent. Dextrose half-life ~2 hours. Electrolytes follow endogenous regulation; no terminal elimination half-life defined.
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
Dextrose is metabolized via glycolysis and the Krebs cycle. Acetate is metabolized in the liver and peripheral tissues to bicarbonate. Electrolytes are not metabolized.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Renal 100% (electrolytes and dextrose metabolized to CO2 and water; excess water and electrolytes excreted unchanged in urine).
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
<5% (minimal; free ions and glucose).
Negligible for electrolytes and dextrose (<5%).
0.2-0.3 L/kg (dextrose and electrolytes distribute primarily in extracellular fluid; total body water for water).
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
Intravenous: 100%.
Intravenous: 100%.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia and fluid overload. For GFR 30-60 m L/min: monitor potassium and fluid status closely; reduce infusion rate and volume.
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
Use with caution in severe hepatic impairment (Child-Pugh C) due to risk of fluid overload and electrolyte imbalances. No specific dose adjustment defined; monitor closely.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
Weight-based: 20-40 m L/kg per dose as a single infusion, rate not to exceed 10 m L/kg/hour. For maintenance: 100-150 m L/kg/day, adjusted for age and clinical status.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
Use with caution due to decreased renal function; consider baseline GFR. Reduce rate and total volume to avoid fluid overload. Monitor electrolytes and volume status frequently.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
None
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
Use with caution in patients with renal impairment, heart failure, or conditions with fluid overload,Risk of electrolyte disturbances (hyperkalemia, hypermagnesemia, hypernatremia) with excessive or rapid infusion,May cause hyperglycemia in patients with diabetes mellitus or glucose intolerance,Avoid in patients with severe metabolic acidosis without adequate buffering capacity,Monitor serum electrolytes, glucose, fluid balance, and acid-base status during prolonged therapy,Not recommended for use in neonates or pediatric patients with significant renal impairment due to potassium content
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Hyperkalemia,Hypernatremia,Severe renal failure with oliguria or anuria,Severe metabolic acidosis (e.g., lactic acidosis, diabetic ketoacidosis),Concurrent administration of medications that may exacerbate hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors),Patients with known allergy to any component
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
No dietary restrictions are required. However, this solution contains dextrose, which may affect blood glucose; diabetic patients should monitor carbohydrate intake accordingly. No known food interactions.
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
First trimester: No known teratogenic effects. Dextrose and electrolytes are physiological components; no structural anomalies reported. Second and third trimesters: No fetal risk; used for fluid and electrolyte maintenance. High dextrose concentrations may cause maternal hyperglycemia, potentially leading to fetal hyperinsulinemia and neonatal hypoglycemia if infused rapidly or in large volumes.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
Dextrose and electrolytes are normal constituents of breast milk. No adverse effects expected. M/P ratio not applicable as components are endogenous.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
No dose adjustment needed for pregnancy-specific pharmacokinetic changes. However, the increased blood volume and glomerular filtration rate may necessitate faster infusion rates to maintain adequate volume; caution to avoid fluid overload. Dextrose infusion rate should be adjusted to maintain maternal blood glucose < 130 mg/d L to prevent fetal hyperinsulinemia.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
PLASMA-LYTE 56 AND DEXTROSE 5% is an isotonic solution containing electrolytes and a low dextrose concentration (5 g/d L). It provides 170 m Osm/L, making it hypotonic relative to plasma. Use cautiously in patients with increased risk of hyponatremia or cerebral edema (e.g., children, elderly, post-op). Co-administration of dextrose may cause hyperglycemia; monitor blood glucose in diabetics. Not for use as a sole source of calories; dextrose concentration insufficient for nutritional support. Contraindicated in patients with hyperkalemia, hypercalcemia, or severe lactic acidosis. Do not administer if solution is discolored or contains particulates.
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
This intravenous solution provides fluids, sugar, and electrolytes to maintain hydration and balance.,Tell your healthcare provider if you have diabetes, kidney disease, heart failure, or electrolyte disorders.,Report any symptoms like headache, nausea, confusion, or swelling during infusion.,This solution is given through a vein; do not adjust the flow rate yourself.,If you experience pain, redness, or swelling at the infusion site, notify your nurse immediately.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte 56 and Dextrose 5% is a crystalloid solution that provides electrolytes and carbohydrates. Dextrose is metabolized to glucose, which is utilized for cellular energy production. The electrolytes (sodium, chloride, potassium, magnesium, and acetate) maintain or restore intravascular volume, acid-base balance, and osmotic gradients. Acetate is metabolized to bicarbonate, providing an alkalinizing effect.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and electrolyte requirements. Typical adult dose: 500-1000 m L as a single infusion, rate up to 333 m L/hour. Maximum 3 L/24 hours.. The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. First trimester: No known teratogenic effects. Dextrose and electrolytes are physiological components; no structural anomalies reported. Second and third trimesters: No fetal risk;. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.